Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

This study has been terminated.
Information provided by (Responsible Party):
Orexigen Therapeutics, Inc Identifier:
First received: May 14, 2012
Last updated: April 26, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2015
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):